GENVEC REPORTS PRECLINICAL RESULTS OF TNFERADE TRIAL

A A

GenVec has announced that preclinical findings have shown its anticancer drug TNFerade to inhibit the spread of skin cancer in an animal model.

In the Phase I trial, all the three melanoma patients with solid tumors had complete response when treated with TNFerade and radiation therapy. The study results also showed that direct injection of TNFerade into melanoma tumors decreased tumor size and reduced lymphatic metastasis outside the treatment area.

GenVec is currently enrolling patients with advanced melanoma in a multicenter Phase II clinical study.